Search research articles
Contact Us
Filters
Showing results (51-60 of 129) with videos related to
Page
of 13
Sort By:
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
The Lancet. Haematology
|
August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Cancer
|
March 27, 2018
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy
I Brian Greenwell, Ashley D Staton, Michael J Lee, et al.
American Journal of Hematology
|
January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort
Lapo Alinari, Alejandro Gru, Carl Quinion, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Max J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 129) with videos related to
Sort By:
Page
of 13
American Journal of Hematology
|
September 20, 2018
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Priyanka A Pophali, Andrew Ip, Melissa C Larson, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
The Lancet. Haematology
|
August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Cancer
|
March 27, 2018
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy
I Brian Greenwell, Ashley D Staton, Michael J Lee, et al.
American Journal of Hematology
|
January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort
Lapo Alinari, Alejandro Gru, Carl Quinion, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Max J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.
Page
of 13